Selecting CROs Across the US and Australia for a Phase 2 CNS Study

Seuss+ helped a small biotech compare CROs across the US and Australia for a Phase 2 orphan disease CNS study. Through a structured, data-driven selection process, we helped the sponsor identify the partnership model that best matched the needs of the trial: an Australian CRO leading the study in partnership with a US CRO.

Summary

A small biotech was preparing for a Phase 2 orphan disease CNS study and needed to select the CRO partner, or combination of partners, that could best support the trial.

The sponsor wanted to look beyond location and CRO size. They needed a fair way to compare US and Australian CROs, understand the strengths of different partnership models, and consider cost alongside the study’s operational needs.

We designed and co-ordinated the selection process from initial alignment through RFI, RFP, and bid defense. We assessed each CRO against the same study-specific criteria, giving the sponsor a clear basis for comparing options.

The evaluation led to a different model than appointing a single CRO. An Australian CRO was selected to lead the study in partnership with a US CRO, giving the sponsor access to the capabilities it needed across both regions while supporting cost-effectiveness.

All selection deadlines were met, allowing the sponsor to appoint its CRO partners and achieve first patient in according to the planned study timeline.

Clinical Trial Success in CNS
2
regions compared
2
CROs in the selected partnerships
4
selection stages completed

What Seuss+ Delivered

Cross-Regional CRO Selection Built Around the Study. We designed a selection process that allowed the sponsor to compare CROs of different sizes across the US and Australia against the needs of the Phase 2 study.

We started by aligning on what mattered most for the trial and defining the criteria that would guide the decision. From there, we managed the RFI and RFP before co-ordinating the bid defense process.

Crucially, the assessment did not assume that one CRO needed to do everything. We considered different partnership models and examined how CROs from the two regions could work together.

This gave the sponsor the evidence needed to select an Australian CRO to lead the study in partnership with a US CRO. The chosen model balanced study requirements, regional capabilities, and cost considerations.

We documented the evaluation and decision-making throughout, creating a clear audit trail and giving internal stakeholders and the board confidence in how we reached the final decision.

The Risk/Challenge

M

The sponsor needed to select the right CRO partner for a Phase 2 orphan disease CNS study

M

CROs of different sizes across the US and Australia needed to be compared fairly

M

The sponsor needed to determine whether a single-CRO or multi-CRO model would better support the study

M

Cost needed to be considered alongside capability, regional experience, and study requirements

M

Each potential partner needed to be assessed against consistent criteria

M

Internal stakeholders and the board needed confidence in the final selection

M

The evaluation and decision-making needed to be fully documented

M

CRO selection needed to stay aligned with the planned study start-up timeline

The Results

N

An Australian CRO was selected to lead the study in partnership with a US CRO

N

The sponsor gained a data-driven basis for comparing CROs across two regions

N

CROs of different sizes and different partnership models were assessed against the needs of the study

N

The selected model combined capabilities from Australia and the US while taking cost-effectiveness into account

N

All selection deadlines were met

N

The sponsor achieved first patient in according to the planned study timeline

N

Internal stakeholders aligned around the selected CRO partnership

N

The board had clear evidence supporting how the decision had been reached

N

The CRO evaluation and selection process was fully documented and audit-ready

N

Sponsor-friendly payment terms and KPIs were negotiated to support CRO accountability

How We Helped

Aligned the selection criteria with the specific needs of the Phase 2 CNS study

Designed a tailored process for comparing CROs across the US and Australia

Managed the RFI process

Developed and managed the RFP

Co-ordinated the bid defense process

Compared CROs of different sizes and regional capabilities

Assessed single-CRO and multi-CRO partnership models

Evaluated how CRO capabilities could be combined across the two regions

Supported the decision to appoint an Australian CRO as study lead in partnership with a US CRO

Managed communications with participating CROs throughout the selection

Documented the evaluation and decision-making to create a clear audit trail

Supported internal and board alignment around the selected partnership model

Supported contract negotiations, including payment terms and KPIs

Kept the selection process aligned with the wider study timeline

Frequently Asked Questions

The right CRO does not always need to come from the sponsor's home market or be the largest provider. Comparing CROs across regions can reveal differences in capabilities, operating models, regional experience, and cost. It can also open up partnership models that may not be obvious at the start of the selection process.

Yes. Depending on the needs of the study, combining CROs can give a sponsor access to complementary capabilities across regions. In this case, the evaluation supported an Australian CRO leading the study in partnership with a US CRO.

We begin by defining what the study actually needs and agreeing on the criteria that matter most. We then use those criteria consistently through the RFI, RFP, and bid defense stages. This gives the sponsor a clearer view of capability, fit, operating model, and commercial considerations, with the decision documented throughout.

Schedule a consultation now

 

Key Takeaways

  • A small biotech preparing a Phase 2 orphan disease CNS study needed to compare US and Australian CROs of different sizes, weighing cost alongside the study's operational needs.
  • Seuss+ ran the selection from initial alignment through RFI, RFP, and bid defense, assessing every CRO against the same study-specific criteria.
  • The evaluation looked at both single-CRO and multi-CRO models instead of assuming one CRO had to do everything.
  • An Australian CRO was selected to lead the study in partnership with a US CRO, combining capabilities across both regions while supporting cost-effectiveness.
  • Every selection deadline was met, first patient in was achieved on the planned timeline, and the decision was documented for the board.

When you compare CROs on what the study actually needs, the answer can look different from the one you expected. Here it was two CROs in two regions, and that combination gave the sponsor the capabilities it needed in both markets.

Sabine Hutchison, CEO and Co-Founder of Seuss+

Comparing CROs across regions?

Book a 30-minute call. We will look at whether a single CRO or a regional partnership would serve your study best.

Book an intro call